Japan's Takeda on the hunt for new drugs to support growth
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
AFFORDABILITY of drugs is the single biggest challenge for not just governments looking to keep a lid on healthcare costs, but also for drug makers hunting for growth and pressured to find new treatments to cope with the rapid rise in patients' need for medicines.
The Asia-Pacific region alone bears 25 per cent of the global disease burden, and the problem is amplified by a fast-ageing population and rise in lifestyle-induced diseases in places including Korea and Taiwan, says Gordon Cameron, area vice-president, Asia-Pacific, at Takeda Pharmaceuticals.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
